Compare SVRA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVRA | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2009 | 2005 |
| Metric | SVRA | EYPT |
|---|---|---|
| Price | $5.13 | $13.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $7.33 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.2M | 852.2K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $430.87 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $5.46 |
| 52 Week High | $7.01 | $19.11 |
| Indicator | SVRA | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 46.88 |
| Support Level | $4.95 | $13.61 |
| Resistance Level | $6.15 | $14.54 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 16.85 | 47.10 |
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.